Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis-A Cross-Sectional Study

Int J Environ Res Public Health. 2021 Apr 10;18(8):3983. doi: 10.3390/ijerph18083983.

Abstract

Polymyositis (PM) and dermatomyositis (DM) are autoimmune-mediated multisystemic myopathies, characterized mainly by proximal muscle weakness. A connection between epilepsy and PM/DM has not been reported previously. Our study aim is to evaluate this association. A case-control study was conducted, enrolling a total of 12,278 patients with 2085 cases (17.0%) and 10,193 subjects in the control group (83.0%). Student's t-test was used to evaluate continuous variables, while the chi-square test was applied for the distribution of categorical variables. Log-rank test, Kaplan-Meier curves and multivariate Cox proportional hazards method were performed for the analysis regarding survival. Of the studied 2085 cases, 1475 subjects (70.7%) were diagnosed with DM, and 610 patients (29.3%) with PM. Participants enrolled as cases had a significantly higher rate of epilepsy (n = 48 [2.3%]) as compared to controls (n = 141 [1.4%], p < 0.0005). Using multivariable logistic regression analysis, PM was found only to be significantly associated with epilepsy (OR 2.2 [95%CI 1.36 to 3.55], p = 0.0014), whereas a non-significant positive trend was noted in DM (OR 1.51 [95%CI 0.99 to 2.30], p = 0.0547). Our data suggest that PM is associated with a higher rate of epilepsy compared to controls. Physicians should be aware of this comorbidity in patients with immune-mediated myopathies.

Keywords: autoimmunity; comorbidity; dermatomyositis; epilepsy; polymyositis.

MeSH terms

  • Case-Control Studies
  • Comorbidity
  • Cross-Sectional Studies
  • Dermatomyositis* / epidemiology
  • Epilepsy* / epidemiology
  • Humans
  • Polymyositis* / epidemiology